Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro.
about
Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infectionsThe bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitroShiga Toxin (Stx) Classification, Structure, and FunctionInvestigation of encephalopathy caused by Shiga toxin 2c-producing Escherichia coli infection in mice.Shiga-like toxin B subunit of Escherichia coli as scaffold for high-avidity display of anti-immunocomplex peptidesSpecific egg yolk immunoglobulin as a new preventive approach for Shiga-toxin-mediated diseasesRapid apoptosis induced by Shiga toxin in HeLa cells.Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.Shiga toxin 2 causes apoptosis in human brain microvascular endothelial cells via C/EBP homologous protein.Toxicity of Shiga toxin 1 in the central nervous system of rabbitsTumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3.Relationship between susceptibility to hemolytic-uremic syndrome and levels of globotriaosylceramide in human seraExperimental verocytotoxemia in rabbitsCurrent views on aetiology and management of haemolytic uraemic syndrome.Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.Haemolytic anaemia after childhood Escherichia coli O 157 .H7 infection: are females at increased risk?Shiga toxin pathogenesis: kidney complications and renal failure.New insights into the haemolytic uraemic syndromes.The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice.Biodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice.Shiga toxin in enterohemorrhagic E.coli: regulation and novel anti-virulence strategiesEnterohemorrhagic E. coli (EHEC) pathogenesis.A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.Shiga toxin production and translocation during microaerobic human colonic infection with Shiga toxin-producing E. coli O157:H7 and O104:H4Causes of the haemolytic uraemic syndrome.Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.Serodiagnosis by passive hemagglutination test and verotoxin enzyme-linked immunosorbent assay of toxin-producing Escherichia coli infections in patients with hemolytic-uremic syndrome.Patients with haemolytic uraemic syndrome caused by Escherichia coli O157: absence of antibodies to Vero cytotoxin 1 (VT1) or VT2.Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1.Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipidIn vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2.Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharidesSelective Evolution of Ligands by Exponential Enrichment to Identify RNA Aptamers against Shiga Toxins.Comparison of the relative toxicities of Shiga-like toxins type I and type II for miceCisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cellsSignal transduction pathways involved in enterohemorrhagic Escherichia coli-induced alterations in T84 epithelial permeability.Enhancement of susceptibility to Shiga toxin-producing Escherichia coli O157:H7 by protein calorie malnutrition in mice.Shiga toxin glycosphingolipid receptors in microvascular and macrovascular endothelial cells: differential association with membrane lipid raft microdomainsComparison of binding platforms yields insights into receptor binding differences between shiga toxins 1 and 2
P2860
Q24550740-5E817D94-D715-420A-A326-4069A555E3F6Q24563989-88A406C9-8C98-4963-B216-9785694237BCQ24633154-4607D5C1-21CE-4223-9397-F9356C4FAEDCQ27021676-5AE416B6-030A-4300-B5A0-E88DF5955EA0Q27334562-46DF55BE-3AD0-4045-A431-7A63780D59E6Q28387185-1E222260-FC0D-45B3-9A4E-5C4173F8C772Q28743696-E57950A0-C795-47B1-BF1E-CA5277DE7411Q30310781-7541B085-1464-4E43-8D6D-88A48D03D5AFQ30418998-E06AC366-2B72-480C-A505-A52D8876D0FDQ30440723-595E23A0-7109-4977-89AF-31FAF3F849E4Q30453693-30957742-4474-42B4-ADE5-B6AC36FCF126Q33326649-CDA83510-0331-43F9-ADDC-08EFD54D58B8Q33335748-29916ACA-E570-46F5-9126-FEB4A197BFFDQ33353985-8D923189-BF68-4742-98B6-904F252FBC23Q33375457-E4BE9A7A-F0ED-44B4-B22A-34D8012C3D0EQ33380705-DD7F083E-F6BC-4E64-ABAC-D5392296E0DBQ33389799-9D805F9C-1D2C-4205-810F-9A3B94D3F3F4Q33397541-2AE1858D-7E6E-4A88-B95A-942F90A813F1Q33397724-C32534E9-338A-4A88-BF99-9DD6F16B1932Q33399096-DECECD26-A25C-4630-A19D-0DE7800094C4Q33401560-41F17007-6BAF-4ED9-AF22-DBBBDC312DC2Q33402959-FC91E19F-D261-4688-B725-E173C3D6900BQ33402961-4B86C550-7619-4EB2-B16E-532C79C0A94DQ33410645-35F044B3-DD77-4091-A772-D863DB9B4EDFQ33413792-06C25EF3-9690-4DC6-884F-34B59FB50F0DQ33415947-BC85DE7F-AC9E-4419-A6EC-8E0E1E18BF73Q33418526-4D01257D-FD7B-4E8B-B0C7-91D0771BC17FQ33491633-78F0D0AD-47C4-4103-86D1-0515908BE5FCQ33493218-3D9A4DB6-C384-435F-98AD-633E7DB22F41Q33498518-191CCC7B-1BDC-46B5-B698-8F6C8FA5ADDBQ33503400-1B3A63A8-E333-4AC9-970A-AA743459C19DQ33545441-66CEB63F-DE37-492C-884D-6772AC7ACA11Q33557728-0EC51AAA-2DB3-4582-BA9E-D16DCA81654FQ33563140-D8B1787E-078F-4FE0-977C-B96A83F5E495Q33605233-7274CB65-1235-42DB-B83C-FCF42C34A79DQ33630801-653DB0B4-4A00-49B0-BB94-EAC82C52EF87Q33752597-3CBE9398-6DB1-4CDB-ACEB-7CF48BCFA7A0Q33752654-43954B6E-700B-4F88-9E6D-182A0F0B8518Q33798933-DB037D9A-B70C-4849-BB07-4618AFEF010EQ33801217-6B4CDA56-81D1-48F1-9515-A3FD3CC86AAB
P2860
Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Glycolipid binding of purified ...... i produced verotoxin in vitro.
@en
Glycolipid binding of purified ...... i produced verotoxin in vitro.
@nl
type
label
Glycolipid binding of purified ...... i produced verotoxin in vitro.
@en
Glycolipid binding of purified ...... i produced verotoxin in vitro.
@nl
prefLabel
Glycolipid binding of purified ...... i produced verotoxin in vitro.
@en
Glycolipid binding of purified ...... i produced verotoxin in vitro.
@nl
P2093
P1476
Glycolipid binding of purified ...... i produced verotoxin in vitro.
@en
P2093
Brunton JL
De Grandis S
Lingwood CA
Richardson S
P304
P407
P577
1987-06-01T00:00:00Z